Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Citi
Boehringer Ingelheim
Mallinckrodt
McKinsey
QuintilesIMS
Johnson and Johnson
Accenture
Covington

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,210,705

« Back to Dashboard

Which drugs does patent 6,210,705 protect, and when does it expire?

Patent 6,210,705 protects DAYTRANA and is included in one NDA.

This patent has forty-two patent family members in twenty-eight countries.
Summary for Patent: 6,210,705
Title: Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
Abstract:The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.
Inventor(s): Mantelle; Juan (Miami, FL), Dixon; Terese A. (Miami, FL)
Assignee: Noven Pharmaceuticals, NC. (Miami, FL)
Application Number:09/163,351
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Use;

Drugs Protected by US Patent 6,210,705

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,210,705

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,348,211 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,210,705

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 014062 ➤ Try a Free Trial
Austria 260652 ➤ Try a Free Trial
Australia 1824999 ➤ Try a Free Trial
Australia 752027 ➤ Try a Free Trial
Brazil 9814282 ➤ Try a Free Trial
Canada 2315237 ➤ Try a Free Trial
China 101120934 ➤ Try a Free Trial
China 1368876 ➤ Try a Free Trial
Colombia 4970785 ➤ Try a Free Trial
Czech Republic 20002209 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
QuintilesIMS
Healthtrust
Baxter
Johnson and Johnson
Daiichi Sankyo
Accenture
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot